Tags

Type your tag names separated by a space and hit enter

Miltefosine for new world cutaneous leishmaniasis.
Clin Infect Dis. 2004 May 01; 38(9):1266-72.CI

Abstract

The oral agent miltefosine has demonstrated a >95% cure rate in Indian visceral leishmaniasis. We performed a large, placebo-controlled study of miltefosine therapy (2.5 mg/kg per day orally for 28 days) against cutaneous leishmaniasis in Colombia and Guatemala. In regions in Colombia where Leishmania vianna panamensis is common, the per-protocol cure rates for miltefosine and placebo were 91% (40 of 44 patients) and 38% (9 of 24). These values are similar to historic values for the antimony standard of care and placebo. In regions in Guatemala where L. v. braziliensis and L. mexicana mexicana are common, the per-protocol cure rates were 53% (20 of 38) for miltefosine and 21% (4 of 19) for placebo. The miltefosine rate was lower than historic antimony cure rates of >90%. Miltefosine was well tolerated. Miltefosine is a useful oral agent against cutaneous leishmaniasis due to L. v. panamensis in Colombia but not against leishmaniasis due to L. v. braziliensis in Guatemala.

Authors+Show Affiliations

Consorcio de Investigaciones Bioclinicas, Bogotá, Colombia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15127339

Citation

Soto, J, et al. "Miltefosine for New World Cutaneous Leishmaniasis." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 38, no. 9, 2004, pp. 1266-72.
Soto J, Arana BA, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis. 2004;38(9):1266-72.
Soto, J., Arana, B. A., Toledo, J., Rizzo, N., Vega, J. C., Diaz, A., Luz, M., Gutierrez, P., Arboleda, M., Berman, J. D., Junge, K., Engel, J., & Sindermann, H. (2004). Miltefosine for new world cutaneous leishmaniasis. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 38(9), 1266-72.
Soto J, et al. Miltefosine for New World Cutaneous Leishmaniasis. Clin Infect Dis. 2004 May 1;38(9):1266-72. PubMed PMID: 15127339.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Miltefosine for new world cutaneous leishmaniasis. AU - Soto,J, AU - Arana,B A, AU - Toledo,J, AU - Rizzo,N, AU - Vega,J C, AU - Diaz,A, AU - Luz,M, AU - Gutierrez,P, AU - Arboleda,M, AU - Berman,J D, AU - Junge,K, AU - Engel,J, AU - Sindermann,H, Y1 - 2004/04/09/ PY - 2003/11/14/received PY - 2004/01/04/accepted PY - 2004/5/6/pubmed PY - 2004/5/21/medline PY - 2004/5/6/entrez SP - 1266 EP - 72 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 38 IS - 9 N2 - The oral agent miltefosine has demonstrated a >95% cure rate in Indian visceral leishmaniasis. We performed a large, placebo-controlled study of miltefosine therapy (2.5 mg/kg per day orally for 28 days) against cutaneous leishmaniasis in Colombia and Guatemala. In regions in Colombia where Leishmania vianna panamensis is common, the per-protocol cure rates for miltefosine and placebo were 91% (40 of 44 patients) and 38% (9 of 24). These values are similar to historic values for the antimony standard of care and placebo. In regions in Guatemala where L. v. braziliensis and L. mexicana mexicana are common, the per-protocol cure rates were 53% (20 of 38) for miltefosine and 21% (4 of 19) for placebo. The miltefosine rate was lower than historic antimony cure rates of >90%. Miltefosine was well tolerated. Miltefosine is a useful oral agent against cutaneous leishmaniasis due to L. v. panamensis in Colombia but not against leishmaniasis due to L. v. braziliensis in Guatemala. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/15127339/Miltefosine_for_new_world_cutaneous_leishmaniasis_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/383321 DB - PRIME DP - Unbound Medicine ER -